Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study

OBSERVE-PD was a cross-sectional, multicountry, observational study conducted in 128 Movement Disorders Centers (MDCs) in 18 countries. Overall, the study enrolled 2615 patients. The aim was to determine the proportion of patients with advanced Parkinson's disease (APD) versus non-APD from MDCs and to uncover the clinical burden of APD, as well as a correlation between overall assessment of APD and several indicators of APD. The advanced stage of the disease and severity were assessed by investigators using their clinical judgement. Data were collected during a single visit between February 2015 and January 2016. Agreement on physician judgement of APD diagnosis and fulfillment of at least one previously established APD indicator was calculated. Motor and nonmotor symptoms (NMSs), activities of daily living, treatment complications, quality of life (QoL), conventional treatments, and device-aided therapy (DAT) eligibility were assessed. Here, country-specific results of 161 Romanian patients with PD are presented. In total, 59.0% of patients were diagnosed with APD and 78.8% met at least one APD indicator. There was only moderate agreement between clinical judgement of APD and overall fulfillment of APD indicators. All scores related to motor symptoms, NMSs, and treatment complications, as well as to QoL, showed a higher disease burden for patients with APD versus non-APD. Physicians considered 73.7% of patients with APD eligible for DAT. The majority of patients eligible for DAT (54.3%) did not receive such treatment. Our results highlight the importance of earlier recognition of APD, by combining clinical judgement with more standardized clinical tools, such as generally recognized APD criteria. However, timely diagnosis of APD alone is not enough to improve patient outcomes. Other critical factors include patient acceptance and access to appropriate treatment.

[1]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  K. Orbán-Kis,et al.  Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients , 2020, Neuropsychiatric disease and treatment.

[3]  A. Antonini,et al.  Efficacy, safety and patient’s quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease in Romania: Results from GLORIA observational study , 2020 .

[4]  Z. Pirtošek,et al.  Update on the Management of Parkinson's Disease for General Neurologists , 2020, Parkinson's disease.

[5]  K. Orbán-Kis,et al.  Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients , 2019, Neuropsychiatric disease and treatment.

[6]  H. Yehia MANAGE-PD: A clinician-reported tool to identify patients with Parkinson's disease inadequately controlled on oral medications – results from vignette-based validation , 2019, Journal of the Neurological Sciences.

[7]  V. Fung,et al.  Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients , 2019, BMC Neurology.

[8]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[9]  A. Antonini,et al.  Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach , 2018, Current medical research and opinion.

[10]  C. Sampaio,et al.  International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[11]  E. Tolosa,et al.  Validation of a simple screening tool for early diagnosis of advanced Parkinson’s disease in daily practice: the CDEPA questionnaire , 2018, npj Parkinson's Disease.

[12]  Pablo Martinez-Martin,et al.  Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed , 2017, Journal of Neural Transmission.

[13]  D. Weiss,et al.  Classification of advanced stages of Parkinson’s disease: translation into stratified treatments , 2017, Journal of Neural Transmission.

[14]  E. Dietrichs,et al.  Algorithms for the treatment of motor problems in Parkinson's disease , 2017, Acta neurologica Scandinavica.

[15]  E. Tolosa,et al.  Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study) , 2017, Parkinson's disease.

[16]  C. Popescu,et al.  The effect of levodopa–carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience , 2015, Journal of Neural Transmission.

[17]  E. Dietrichs,et al.  Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. , 2015, Parkinsonism & related disorders.

[18]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[19]  I. Forgacs,et al.  Perceptions of symptoms and expectations of advanced therapy for Parkinson’s disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson’s disease (PRO-APD) , 2014, Health and Quality of Life Outcomes.

[20]  B. Bloem,et al.  Moving from physician-centered care towards patient-centered care for Parkinson's disease patients. , 2013, Parkinsonism & related disorders.

[21]  J. Kulisevsky,et al.  Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I) , 2013 .

[22]  P. Worth When the going gets tough: how to select patients with Parkinson's disease for advanced therapies , 2013, Practical Neurology.

[23]  G. Deuschl,et al.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.

[24]  M. McHugh Interrater reliability: the kappa statistic , 2012, Biochemia medica.

[25]  S. Pedersen,et al.  Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic , 2012, The open neurology journal.

[26]  A. Spottke,et al.  Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease , 2012, Journal of the Neurological Sciences.

[27]  A. Cronin-Golomb,et al.  Relation of Subjective Quality of Life to Motor Symptom Profile in Parkinson's Disease , 2011, Parkinson's disease.

[28]  S. Varanese,et al.  Treatment of Advanced Parkinson's Disease , 2011, Parkinson's disease.

[29]  Marios Politis,et al.  Parkinson's disease symptoms: The patient's perspective , 2010, Movement disorders : official journal of the Movement Disorder Society.

[30]  C. Clarke,et al.  Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.

[31]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[32]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[33]  M. Jahanshahi,et al.  Quality of life in Parkinson's disease: The relative importance of the symptoms , 2008, Movement disorders : official journal of the Movement Disorder Society.

[34]  M. van den Akker,et al.  Coronary heart disease and cardiovascular risk factors among people aged 25–65 years, as seen in Romanian primary healthcare , 2008, The European journal of general practice.

[35]  R. Fitzpatrick,et al.  Cross-cultural evaluation of the short form 8-item Parkinson's Disease Questionnaire (PDQ-8): results from America, Canada, Japan, Italy and Spain. , 2007, Parkinsonism & related disorders.

[36]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[37]  H. Glick,et al.  Preference-based quality-of-life in patients with Parkinson’s disease , 2002, Neurology.

[38]  A Schrag,et al.  How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population , 2000, Movement disorders : official journal of the Movement Disorder Society.

[39]  George Wright,et al.  The Delphi technique as a forecasting tool: issues and analysis , 1999 .

[40]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[41]  M. Stewart Effective physician-patient communication and health outcomes: a review. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  Murray Turoff,et al.  The Delphi method : techniques and applications , 1976 .

[43]  N. Dalkey,et al.  An Experimental Application of the Delphi Method to the Use of Experts , 1963 .

[44]  C. Redecker,et al.  Advanced stages of PD: interventional therapies and related patient-centered care , 2015, Journal of Neural Transmission.

[45]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[46]  W. Weiner An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. , 2002, Neurology.

[47]  George Wright,et al.  Expert Opinions in Forecasting: The Role of the Delphi Technique , 2001 .

[48]  H Sackman,et al.  Delphi Assessment: Expert Opinion, Forecasting, and Group Process , 1974 .

[49]  Bernice B Brown,et al.  DELPHI PROCESS: A METHODOLOGY USED FOR THE ELICITATION OF OPINIONS OF EXPERTS , 1968 .